Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma - guidance (TA465)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
09 August 2017

Abstract

Evidence-based recommendations on olaratumab (Lartruvo) plus doxorubicin for advanced soft tissue sarcoma in adults.

 January 2019: The European Medicines Agency (EMA) has issued a press release following preliminary results from the ANNOUNCE study. ANNOUNCE is a phase 3 study of olaratumab with doxorubicin in people with advanced or metastatic soft tissue sarcoma. Early results show that olaratumab is not more effective at prolonging the lives of people compared with doxorubicin alone (a standard care treatment). The EMA have advised that no new people should start treatment with olaratumab and NHS England have confirmed that the Cancer Drugs Fund will not fund any new people, while full results from the study are awaited. People taking olaratumab and appearing to benefit from it, should talk to their doctor about their continued treatment or other treatment options. Further updates will be provided as the situation progresses.

Is this guidance up to date?

Next review: More evidence on olaratumumab is being collected, until December 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Commercial arrangement

There is a managed access agreement, which includes a commercial access agreement for olaratumumab. Contact UKPricing@lilly.com for details.

Guidance development process

How we develop NICE technology appraisal guidance